Giancarlo Mercogliano is a Gastroenterology physician affiliated with Lankenau Medical Center. OpenAlex indexes 43 publications with 357 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
100 E Lancaster Ave
Lankenau Medical Building East Suite 252
Wynnewood, PA 190963450
Telephone
610-896-7360Registry record last updated 2 Nov 2007.
Industry payments
31 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Takeda Pharmaceuticals U.S.A., Inc.Program year20251 payment
- Salix Pharmaceuticals, a division of Bausch Health US, LLCProgram year202419 payments
- ABBVIE INC.Program year202416 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
92%Proton pump inhibitor62.7%Omeprazole50%Pantoprazole Sodium29%Esomeprazole Magnesium7%Lansoprazole6%Dexlansoprazole Dr5%Dexilant3%Part D<11 patientsH2 blocker16.1%Famotidine100%Part D≥32 patients+ 4 more classes in this area
Cancer & immunology
6.2%Interleukin-12 Antagonist6.2%Stelara100%Part D<11 patientsCardiovascular
1.8%Bile Acid Sequestrant1.8%Colestipol Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Orally Administered Zinc Gluconate Induces Tight Junctional Remodeling and Reduces Passive Transmucosal Permeability Across Human Intestine in a Patient-Based Study
International Journal of Molecular Sciences
2025 - 1819: A RCT on lifestyle and microbiota in prostate cancer pts undergoing RT: MICROSTYLE study.
Radiotherapy and Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
John Marks, MD
Lankenau Medical Center
Stephen Gollomp, MD
Lankenau Medical Center
Sandra Abramson, MD
Lankenau Medical Center
Jeanine Romanelli, MD
Lankenau Medical Center
Charles Rice, MD
The Rockefeller University
Edward Loftus, MD
Mayo Clinic Rochester
Naga Chalasani, MD
Indiana University School of Medicine
Bruce Sands, MD
Icahn School of Medicine at Mount Sinai
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”